Volume No. :   8

Issue No. :  4

Year :  2018

ISSN Print :  2231-5667

ISSN Online :  2231-5675


Allready Registrered
Click to Login

Azilsartan: A Review of Analytical Methods for estimation in Pharmaceutical Formulation

Address:   Zamir G. Khan, Sanjaykumar B. Bari, Sarang N. Gujarathi, Shivam B. Gujarathi, Prashant B. Patil*
Department of Pharmaceutical Chemistry, H. R. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dist: Dhule (MS) 425405 India
*Corresponding Author
DOI No: 10.5958/2231-5675.2018.00041.8

Azilsartan medoxomil was approved by the United States Food and Drug Administration in 2011. AZL is used for the treatment of essential hypertension and has publicized promising results in blood pressure (BP) reduction and tolerability, but has not yet been considered into practice as compared to other angiotensin II receptor blockers (ARBs). AZL lowers blood pressure by blocking the action of angiotensin II at the AT1 receptor, a hormone that contracts blood vessels and reduces water excretion through the kidneys. There have been numerous methods developed so far for quantitative estimation of AZL in bulk and pharmaceutical dosage form. Pharmaceutical analytical methods include UV Visible Spectrophotometry, High Pressure Thin Layer Chromatography, Reversed Phase High Performance Liquid Chromatography and hyphenated techniques like Liquid chromatography- Mass Spectrometry. This review paper includes publications form 2010 to 2018. The chromatographic methods primarily RP-HPLC and LC-MS found more accurate, precise and sensitive compared to other pharmaceutical methods. AZL shows greater extent of degradation up to 40% with hydrogen peroxide. AZL is degraded up to 38% and 31% with acidic and neutral pH respectively while it shows greater photo stability and dry heat.
UV – Visible Spectrophotometry, HPTLC, RP-HPLC, LC-MS, Azilsartan, Validation, stability indicating methods.
Prashant B. Patil. Azilsartan: A Review of Analytical Methods for estimation in Pharmaceutical Formulation. Asian J. Pharm. Ana. 2018; 8(4): 227-232.
[View HTML]     

Visitor's No. :   198320